摘要
目的观察肺癌1号方对非小细胞肺癌患者的近期疗效和免疫功能以及血清血管内皮生长因子(VEGF)、角质蛋白21-1(CYFRA21-1)的影响。方法将100例非小细胞肺癌患者随机分为肺癌1号方治疗组52例、化疗组48例,治疗组口服中药肺癌1号方,化疗组采用GP方案或TP方案化疗2个疗程,治疗前后检测患者免疫功能及血清VEGF、CYFRA21-1。结果肺癌1号方治疗组肿瘤近期疗效为76.92%,优于化疗组的43.75%(P<0.01);肺癌1号方治疗组KPS评分提高稳定率为86.54%,高于化疗组的27.08%(P<0.01);T细胞总数、辅助性T细胞及NK细胞水平均高于化疗组,而抑制性T细胞水平及VEGF、CYFRA21-1水平均低于化疗组。结论肺癌1号方能延长非小细胞肺癌患者生存时间,改善生活质量,增强免疫功能,抑制肿瘤细胞的活动。
Objective To observe the recent effect and influence of Lung Cancer Fang No.1 on immunologic function and serum vessel endothelia growth factor （VEGF）, keratoprotein 21-1 （CYFRA21-1） in non-small cell lung cancer patients （NSCLC）. Methods One hundred non-small ceil lung cancer patients were randomized into 52 cases of treatment group on Lung Cancer Fang No.1 and 48 cases of chemotherapy group. The treatment group was treated by Lung Cancer Fang No.1, and the chemotherapy group by GP or TP programme for 2 treatment courses. Immune function indexes, serum VEGF and CYFRA21-1 were determined before and after treatment. Results Efficacy for the treatment group recently was 76.92%, better than 43.75% of the chemotherapy group （P〈0.01）. Treatment group increased stability KPS score was 86.54%, higher than 27.08% of the chemotherapy group （P〈0.01）. The total number of T cells, helper T cells and NK cells were higher than that in the chemotherapy group, and inhibition of T cell and VEGF, CYFRA21-1 level lower than the chemotherapy group. Conclusion Lung Cancer Fang No.1 can lengthen the non-small cell lung cancer patient life, improve quality of life, enhance immune function and suppress the activity of tumour cell.
出处
《中国中医药信息杂志》
CAS
CSCD
2008年第11期9-11,共3页
Chinese Journal of Information on Traditional Chinese Medicine
